News 2017-10-27
2018 CPhI WW — A Window to the Global Pharmaceutical Supply Chain
Continuing a long and respected tradition, CPhI WW’s Annual Meeting was held during October 24-26, 2017 at the Messe Frankfurt Exhibition Center, Germany. As the world’s leading exhibition and meeting place in the area of pharmaceutical ingredients, the event brought global pharmaceutical companies, manufacturers and professionals together in a joint quest for continued supply chain innovation, reliability and quality.
As a top-tier external manufacturing partner and strategic supplier of custom drug intermediates and APIs to many of the world’s leading pharmaceutical companies, a high-powered Porton delegation led by Chairman & CEO Mr. Oliver Ju attended this marquee 3-day event. Porton’s executives had more than 70 meetings with customers at over 50 global pharmaceutical companies including 12 of the Top 20 Big Pharma, such as Janssen, Gilead, Pfizer, Novartis and etc. We also met with dozens of specialty pharmaceutical and biotechnology companies across the US and Europe in reference to ongoing and projected R&D and external manufacturing collaborations.
Also continuing a recently set precedent, Porton hosted a Wine + Tapas Social at our booth for customers, industry stakeholders and media on Wednesday, October 25, 2017. Featuring music, French wines and small plate appetizers, Porton’s executives cultivated valued relationships with many customers and prospective partners during this informal late afternoon event – setting the stage for additional future discussions.
Others
More
News 2025-07-31
Porton Participates in Publishing an OPRD Paper, Demonstrating Strength in Drug Synthesis Technology
Metal catalytic and DoE technologies for the optimization of CT1812 synthesis routes
News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.
